JPMorgan lowered the firm’s price target on Organon (OGN) to $12 from $14 and keeps an Underweight rating on the shares. The firm reduced estimates citing Nexplanon and respiratory headwinds post the earnings report.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OGN:
- Organon price target lowered to $9 from $10 at Morgan Stanley
- Organon & Co. Reports Modest Q3 Revenue Growth
- Midday Fly By: Insurers slip as Senate spending bill lacks ACA extension
- Morning Movers: Monday.com sinks following third quarter results
- Organon cuts FY25 revenue view to $6.2B-$6.25B from $6.28B-$6.38B